美国胃肠病学会小肠细菌过度生长临床实践更新:专家综述
美国胃肠病学会发布小肠细菌过度生长(SIBO)临床实践更新,由3位作者基于文献综述经讨论、修改和共识形成9条最佳实践建议,内容涵盖SIBO定义、症状、诊断标志物、病理生理争议、治疗原则及抗生素策略的局限性。
要点
- SIBO定义缺乏精确性和一致性,通常指归因于小肠细菌数量或组成变化的临床 disorder。
- 传统相关症状包括腹胀、腹泻和腹痛/不适,严重病例可见脂肪泻。
- 管理应侧重识别和纠正潜在病因、纠正营养缺乏及使用抗生素,尤其对明显消化不良和吸收不良者。
核心结论
- SIBO定义缺乏精确性和一致性,其真实患病率因此未能确定。
- 管理应侧重识别和尽可能纠正潜在病因、纠正营养缺乏及使用抗生素,对明显消化不良和吸收不良者尤为重要。
- 关于SIBO在功能性症状(如肠易激综合征组分)发病中的作用仍存争议。
- 肠易激综合征对难吸收抗生素治疗有应答,但SIBO或其根除在该应答产生中的作用需随机对照试验进一步确认。
研究设计与样本
- 最佳实践建议由3位作者经讨论形成,2位作者分别基于现有文献综述撰写部分建议文本,全部作者审阅完整草稿并经讨论、重写和进一步审阅修订后达成一致。
主要发现
- 传统上与SIBO相关的症状包括腹胀、腹泻和腹痛/不适,更严重病例可见脂肪泻。
- 实验室检查可包括叶酸升高,以及较少见的维生素B-12缺乏或其他营养缺乏。
- 证据不足以支持使用炎症标志物(如粪便钙卫蛋白)检测SIBO。
- 准确界定SIBO的主要障碍是对正常小肠微生物群了解有限。
- 指导临床医生制定SIBO抗生素策略的数据库有限,治疗在很大程度上仍为经验性。
关键数值与推荐
- 最佳实践建议1:SIBO作为临床实体的定义缺乏精确性和一致性。
- 最佳实践建议2:传统相关症状包括腹胀、腹泻和腹痛/不适,更严重病例可见脂肪泻。
- 最佳实践建议3:证据不足以支持使用炎症标志物(如粪便钙卫蛋白)检测SIBO。
- 最佳实践建议4:实验室检查可包括叶酸升高和较少见的维生素B-12缺乏或其他营养缺乏。
- 最佳实践建议7:管理应侧重识别和尽可能纠正潜在病因、纠正营养缺乏及使用抗生素。
临床怎么用
- 管理应侧重识别和尽可能纠正潜在病因、纠正营养缺乏及使用抗生素,对明显消化不良和吸收不良者尤为重要。
- 尽管肠易激综合征对难吸收抗生素治疗有应答,SIBO或其根除在该应答中的作用需随机对照试验进一步确认。
- 指导SIBO抗生素策略的数据库有限,治疗在很大程度上仍为经验性,但必须始终注意长期广谱抗生素治疗的潜在风险。
局限性
- SIBO定义缺乏精确性和一致性,真实患病率 accordingly 未能确定。
- 准确界定SIBO的主要障碍是对正常小肠微生物群了解有限。
- 关于SIBO在常见功能性症状(如肠易激综合征组分)发病中的作用仍存争议。
- 指导临床医生制定SIBO抗生素策略的数据库有限。
- SIBO或其根除在肠易激综合征对抗生素应答中的作用需随机对照试验进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth (SIBO) is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even nongastrointestinal symptoms and is increasingly implicated in lay press and media in the causation of a diverse array of disorders. Its definition, however, remains controversial and true prevalence, accordingly, undefined. The purpose of this review, therefore, was to provide a historical background to the concept of SIBO, critically review current concepts of SIBO (including symptomatology, pathophysiology, clinical consequences, diagnosis and treatment), define unanswered questions and provide a road map toward their resolution. METHODS: Best Practice Advice statements were developed following discussion by the 3 authors. Two authors each developed text around certain Best Practice Advice based on a review of available literature. All 3 authors reviewed the complete draft and after discussion, redrafting, and further review and revision, all of the authors agreed on a final draft. BEST PRACTICE ADVICE 1: The definition of SIBO as a clinical entity lacks precision and consistency; it is a term generally applied to a clinical disorder where symptoms, clinical signs, and/or laboratory abnormalities are attributed to changes in the numbers of bacteria or in the composition of the bacterial population in the small intestine. BEST PRACTICE ADVICE 2: Symptoms traditionally linked to SIBO include bloating, diarrhea, and abdominal pain/discomfort. Steatorrhea may be seen in more severe cases. BEST PRACTICE ADVICE 3: There is insufficient evidence to support the use of inflammatory markers, such as fecal calprotectin to detect SIBO. BEST PRACTICE ADVICE 4: Laboratory findings can include elevated folate and, less commonly, vitamin B-12 deficiency, or other nutritional deficiencies. BEST PRACTICE ADVICE 5: A major impediment to our ability to accurately define SIBO is our limited understanding of normal small intestinal microbial populations-progress in sampling technology and techniques to enumerate bacterial populations and their metabolic products should provide much needed clarity. BEST PRACTICE ADVICE 6: Controversy remains concerning the role of SIBO in the pathogenesis of common functional symptoms, such as those regarded as components of irritable bowel syndrome. BEST PRACTICE ADVICE 7: Management should focus on the identification and correction (where possible) of underlying causes, correction of nutritional deficiencies, and the administration of antibiotics. This is especially important for patients with significant maldigestion and malabsorption. BEST PRACTICE ADVICE 8: Although irritable bowel syndrome has been shown to respond to therapy with a poorly absorbed antibiotic, the role of SIBO or its eradication in the genesis of this response warrants further confirmation in randomized controlled trials. BEST PRACTICE ADVICE 9: There is a limited database to guide the clinician in developing antibiotic strategies for SIBO, in any context. Therapy remains, for the most part, empiric but must be ever mindful of the potential risks of long-term broad-spectrum antibiotic therapy.
引用
- Quigley EMM, Murray JA, Pimentel M, et al. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020. PMID: 32679220. doi:10.1053/j.gastro.2020.06.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。